Impact of urate-lowering therapy on quality of life indicators in patients with gout

Gout can have a significant impact on the quality of life (QoL) patients. Objective: to assess dynamics QoL indicators and possibility achieving target level uric acid (UA) in patients with gout febuxostat therapy, ineffectiveness / or contraindications allopurinol administration. Patients methods. The prospective, single-center study included 80 gout. follow-up period was at least 6 months (Azurix®) therapy doses required achieve UA level. When urate-lowering initiated, 100 mg per day prescribed, followed by dose titration (up maximum 900 day) until reached (<360 μmol/L). adverse reactions (ADRs) were transferred 80–120 day. To prevent arthritis attacks, all received low non-steroidal anti-inflammatory drugs colchicine 0.5 glucocorticoids 7,5 (in prednisolone equivqlent). At first last visits, completed SF-36 questionnaire. Results discussion. After follow-up, 70 (88%) whom 51 (73%) Allopurinol dosage 26 patients, 14 (54%) achieved treatment goal. Due allopurinol, 32 switched febuxostat, which allowed normouricemia 69% cases. Fifteen (68%) 22 who initiated due ADRs also improved indicators: role-physical functioning, bodily pain, general health, vitality physical well-being (p<0.05 cases). did not reach such as pain High compliance observed 63% treated 36% allopurinol. Conclusion. In intolerance cases allows improving complience.